Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/03/2023* 01:00 EST Earnings Call Q4 2022 -- -- --
07/27/2022* -- Results Q2 2022 -- -- --
02/03/2022 -- Results Q4 2021 -- -- --
02/03/2022 01:00 EST Earnings Call Q4 2021 -- -- --
07/27/2021 -- Results Q2 2021 -- -- --
02/04/2021 -- Results Q4 2020 -- -- --
02/04/2021 08:00 EST Earnings Call Q4 2020 -- -- --
10/15/2020 -- Results Q3 2020 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/27/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade
 
4.00
2.00
1.00
 
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
No data available
Last Report Date 02/03/2022
Beat/Miss Upgrade
Return Since -12.09%
Last FQE 12/31/2021
Next FQE 03/31/2022

Profile

Edit
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
URL https://www.roche.com
Investor Relations URL https://www.roche.com/investors.htm
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 27, 2022 (est.)
Last Earnings Release Feb. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 17, 2022

Dividends

Dividend Per Share (TTM) 1.262
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.396
Yield to Sector 1.482
Yield to Industry 0.7995
Last Dividend Amt. 1.241
Dividend Frequency Annually
Last Ex-Dividend Date Mar. 17, 2022
Yield (TTM) 3.08%
Forward Yield 3.07%
Payout Ratio 56.10%
Cash Payout Ratio 47.68%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
4.48%
-14.61%
14.32%
2.08%
35.02%
10.97%
21.42%
-19.88%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.74%
-4.67%
-12.13%
19.40%
5.88%
14.34%
3.41%
-3.82%
4.69%
--
--
--
--
--
--
--
-47.75%
--
--
-1.39%
-26.17%
-9.84%
-39.32%
-4.26%
-37.37%
--
--
15.89%
21.68%
113.2%
151.4%
-50.51%
-28.27%
As of May 17, 2022.

Profile

Edit
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
URL https://www.roche.com
Investor Relations URL https://www.roche.com/investors.htm
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 27, 2022 (est.)
Last Earnings Release Feb. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 17, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
THW 31.19M USD 5.31%
MPGFX 159.35M USD 2.93%
DSTX 598911.0 USD 2.61%
LGRCX 342.74M USD 2.61%
CBBRX 53.65M USD 2.60%
PIEMX 241.30M USD 2.30%
MBCNX 45.16M USD 1.21%
SATOX 29.00M USD 0.70%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership